Results 11 to 20 of about 9,830 (184)
Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. [PDF]
PLoS ONE, 2013 Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of ...
Maarten van Dinther +10 more
doaj +6 more sources
Sclerostin and Vascular Pathophysiology [PDF]
International Journal of Molecular Sciences, 2020 There is cumulating evidence for a contribution of Wnt signaling pathways in multiple processes involved in atherosclerosis and vascular aging. Wnt signaling plays a role in endothelial dysfunction, in the proliferation and migration of vascular smooth muscle cells (VSMCs) and intimal thickening.
Catalano A. +3 more
openaire +3 more sources
eLife, 2021 The downregulation of sclerostin in osteocytes mediates bone formation in response to mechanical cues and parathyroid hormone (PTH). To date, the regulation of sclerostin has been attributed exclusively to the transcriptional downregulation of the Sost ...
Nicole R Gould +11 more
doaj +1 more source
Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? [PDF]
Folia Medica, 2023 Introduction: Sclerostin is a glycoprotein known as a negative regulator of bone formation, predominantly expressed by mature osteocytes.
Ilhan Sabancilar +4 more
doaj +3 more sources
Inhibitors of sclerostin [PDF]
Current Opinion in Rheumatology, 2014 Recent data suggest that inhibitors of sclerostin, an osteocyte-produced Wnt signaling pathway antagonist, can stimulate bone formation. This review provides rationale and summarizes recent evidence supporting this novel approach to skeletal anabolism.Data from numerous preclinical models in rodents and monkeys consistently demonstrate that ...
Matthew T, Drake, Joshua N, Farr
openaire +2 more sources
The Role of Sclerostin in Bone Diseases [PDF]
Journal of Clinical Medicine, 2022 Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin’s origin, regulation, and mechanism of action.
Elias S. Vasiliadis +5 more
openaire +3 more sources
Journal of Osteoporosis, 2010 The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
openaire +3 more sources
Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice [PDF]
Open Biology, 2019 Osteocytes secrete the glycoprotein sclerostin to inhibit bone formation by osteoblasts, but how sclerostin production is regulated in osteocytes remains unclear.
Wen Liu +14 more
doaj +1 more source
Sclerostin regulation: a promising therapy for periodontitis by modulating alveolar bone
Chinese Medical Journal, 2020 . Periodontitis is one of the most prevalent epidemics affecting human health and life recently, and exploration of the pathogenesis and treatment of periodontitis has been valued by scholars.
Tian-Jiao Li +5 more
doaj +1 more source
Sclerostin and Cardiovascular Disease
Current Osteoporosis Reports, 2023 Abstract Purpose of Review The role of wnt signalling in atherogenesis raises the possibility that the wnt inhibitor, sclerostin, provides a natural defence to this process, and that anti-sclerostin antibodies might increase the risk of atherosclerosis and associated conditions such as CVD.
openaire +3 more sources